Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

被引:0
作者
Georgia Kourlaba
John Parissis
Apostolos Karavidas
Alexandra Beletsi
Charalambos Milonas
Neil Branscombe
Nikos Maniadakis
机构
[1] National and Kapodistrian University of Athens,The Stavros Niarchos Foundation
[2] School of Medicine,Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO)
[3] Attikon University Hospital,Department of Cardiology
[4] Athens General Hospital “Georgios Genimmatas”,Department of Cardiology
[5] Servier Hellas Pharmaceuticals Ltd,Department of Health Services Organization & Management
[6] National School of Public Health,undefined
[7] Servier Laboratories Ltd,undefined
来源
BMC Health Services Research | / 14卷
关键词
Cost-effectiveness; Heart failure; Ivabradine; Cost-utility;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 61 条
[1]  
Krum H(2006)Chronic heart failure: time to recognize this major public health problem Med J Australia 184 147-148
[2]  
Stewart S(2007)Clinical epidemiology of heart failure Heart 93 1137-1146
[3]  
Mosterd A(2000)Survival of patients with a new diagnosis of heart failure: a population based study Heart 83 505-510
[4]  
Hoes AW(2012)ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 1787-1847
[5]  
Cowie MR(2008)Economic burden of heart failure in the elderly Pharmacoeconomics 26 447-462
[6]  
Wood DA(2007)Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 6 127-139
[7]  
Coats AJ(2010)Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 875-885
[8]  
Thompson SG(2004)Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health: J Int Soc Pharm Outcomes Res 7 518-528
[9]  
Suresh V(2004)Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 437-452
[10]  
Poole-Wilson PA(2004)Cost-effectiveness acceptability curves–facts, fallacies and frequently asked questions Health Econ 13 405-415